EGFR and lung carcinoma: The implication of these results is that combination therapy will be effective in a select group of patients with lung cancer, and while this initial data is promising given the development of EGFR resistance and lack of therapeutic options in the context of SCC, further refinement is necessary in defining appropriate patient subsets for this treatment.